|
|
CN
Online Message×
Click switch

Containcovid-19Content

Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
More
Jan 07,2022
DRUG DISCOVERY 2021: RECONNECT WITH MEDICILON

DATE: 19-20 Oct, 2021

LOCATION: The exhibition center, ACC, Liverpool

More
Nov 18,2021
Consistency Evaluation of Oral Solid Dosage
As of May 2019, starting from the formal acceptance of the first conformity evaluation product in 2017, there have been nearly 900 oral solid dosage forms for conformity evaluation. The dosage forms include tablets, capsules, powders, sustained-release capsules, etc. At present, more than 200 product specifications have passed the consistency evaluation. The consistency evaluation ofRead more
More
Oct 28,2021
Yeast Expression System and Method
The Production of Yeast Expression System The development of genetic engineering technology has shown broad prospects for the synthesis and production of foreign proteins by microorganisms. For a long time, people have used E. coli as a host to express a variety of proteins. This is because E. coli has several advantages, such as clearRead more
More
Oct 13,2021
Key Material Attributes of API Particle Size in Formulation Development
The particle size of the API, as a key material attribute in the development of formulations, not only affects the powder properties of the API (such as fluidity), the uniformity of the formulation content, the chemical stability of the API and the formulation, but also affects the dissolution of the formulation, which in turn affectsRead more
More
Oct 11,2021
Medicilon’s CMC Services: Process and Formulation
Related Articles: The Value and Importance of Preformulation Research
More
Oct 11,2021
Video of Medicilon Preclinical Research Services
Related Articles: What is Preclinical Trails? Integrated Preclinical Trails Services New Drug Preclinical Trails
More
Oct 09,2021
Medicilon Won Four Heavyweight Awards in One Fell Swoop!
“Top 50 Listed Companies for Growth” “Top Ten Entrepreneurship Leaders of Listed Companies” “Excellent Secretary of the Board of Directors of Listed Companies on the
More
Oct 09,2021
Medicilon won the “Science and Innovation Golden Horse Excellent Company Award” at the 2021 Science and Technology Leaders Summit
On July 22, 2019, the Shanghai Sci-Tech Innovation Board (STAR) opened.  Two years later, on July 22, 2021, 313 companies are listed on the STAR. 
More
Sep 26,2021
Come and Join Medicilon at Booth # 114 in DOT

DATE: September 27-30, 2021

LOCATION: 1 Broadway, 9th FL,Cambridge Innovation Center, Cambridge, MA 02142

More
Sep 22,2021
Medicilon is Listed on the “Top Chinese R&D CRO Enterprises in 2021”
On the September 18th to 19th, the Smart China Expo’s important series of events, “2021 Conference on High Quality Development of Healthcare Industry and the
More
Sep 22,2021
Medicilon attended the 21st China International Fair for Investment and Trade
Medicilon attended the 21st China International Fair for Investment and Trade and signed a strategic collaboration agreement with Xiamen Biotime. The 21st China International Fair
More
Sep 22,2021
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop.  From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then
More
Sep 15,2021
The 19th Annual San Diego BioPharma Conference
Agenda 9:00 am Welcome and Opening Remarks Tao Wu, PhD, President, SABPA Yi Liu, PhD, Chair, BioPharmaCommittee, SABPA; CEO, Kumqat Biosciences 9:15 am Floyd Romesberg,
More
Sep 09,2021
Gap in GLP Practice Between China and Foreign Countries
The Code of Quality Management for Non-clinical Research of Drugs, or GLP for short, is the basic principle that must be followed for pre-clinical research of drugs. It is also a fundamental measure to improve the quality of new drug research from the source and ensure the safety of drug use by the people. AfterRead more
More
Sep 07,2021
Medicilon assists Chipscreen Biosciences’ CS12192 to be approved by the FDA
On August 28, 2021, the FDA recently approved the CS12192, a new drug clinical trial application for the treatment of Graft Versus Host Disease (GVHD) independently developed by Chipscreen Biosciences (Chipscreen).  Previously, the drug has obtained clinical approval in China. It is worth mentioning that Shanghai Medicilon Inc. (Medicilon) provides comprehensive preclinical research including pharmacokineticsRead more
More
Aug 04,2021
The experimental principle and operation steps of ELISA
1. Experimental principle ELISA is a highly sensitive test technique based on immunological reaction, which combines the specific reaction of antigen and antibody with the efficient catalysis of enzyme to substrate. Since the reaction of antigen and antibody is carried out in a solid phase carrier — polystyrene microtitration plate, after each addition of aRead more
More
Jun 29,2021
2019 Domestic Class 1 New Drug IND Ranking
In 2019, the development of innovative drugs is still hot, and the number of domestic Class 1 new drug INDs continues to exceed 110, reaching a new high; 8 INDs of Chia Tai Tianqing were accepted by the national CDE, ranking first among all domestic pharmaceutical companies, followed by stone Pharmaceutical Group, Guangdong Dongyang Sunshine,Read more
More
Apr 26,2021
The first CD19 targeting ADC drug is approved, who is leading the ADC market?
A few days ago,ADC Therapeutics SA announced that the FDA has approved its antibody-conjugated drug Zynlonta (loncastuximab tesirine-LPYL) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (R/ R DLBCL) who have previously received 2-line or more systemic therapy. Loncastuximab tesirine (Lonca, formerly known as ADCT-402) is an antibody-conjugated drug (ADC)Read more
More
Apr 26,2021
Something you must know about the yeast two-hybrid system
Yeast two-hybrid Yeast two-hybrid, proposed by Fields in 1989, is primarily used to analyze the gene system for protein-protein interactions in yeast and is a genetic method for the module structure of transcription factors. The yeast two-hybrid system was developed in eukaryotic model yeast to study protein interactions in living cells, and weak, transient interactionsRead more
More